checkAd

     153  0 Kommentare Homology Medicines Declares Distribution to Common Stockholders - Seite 2

    About Homology Medicines

    Homology Medicines, Inc. is a clinical-stage genetic medicines company historically focused on transforming the lives of patients suffering from rare diseases, by addressing the underlying cause of the disease. Homology Medicines has gene editing and gene therapy clinical-stage programs in phenylketonuria (PKU) and Hunter syndrome (MPS II), a preclinical pipeline that includes a gene therapy candidate for metachromatic leukodystrophy and a GTx-mAb (vectorized antibody) candidate for paroxysmal nocturnal hemoglobinuria, as well as intellectual property on its family of 15 adeno- associated viruses (AAVHSCs). Homology Medicines is not currently pursuing further development of these programs and is pursuing strategic options for the Company and its programs and platform technology. Additionally, the Company has an ownership stake in Oxford Biomedica (US) LLC (formerly Oxford Biomedica Solutions LLC), an AAV manufacturing company based on Homology Medicines’ internal process development and manufacturing formed as a joint venture between Homology Medicines and Oxford Biomedica plc. For more information, visit www.homologymedicines.com.

    No Offer or Solicitation

    This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    Lesen Sie auch

    Homology Contact:
    Paul Alloway
    President and Chief Operating Officer
    (781) 327-2633
    palloway@homologymedicines.com


    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Homology Medicines Declares Distribution to Common Stockholders - Seite 2 BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) - Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive …

    Schreibe Deinen Kommentar

    Disclaimer